CERO (CERo Therapeutics Holdings) Total Assets : $6.49 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Total Assets?

CERo Therapeutics Holdings's Total Assets for the quarter that ended in Sep. 2024 was $6.49 Mil.

Total Assets is connected with ROA %. CERo Therapeutics Holdings's annualized ROA % for the quarter that ended in Sep. 2024 was -243.99%. Total Assets is also linked to Revenue through Asset Turnover. CERo Therapeutics Holdings's Asset Turnover for the quarter that ended in Sep. 2024 was 0.00.

CERo Therapeutics Holdings Total Assets Historical Data

The historical data trend for CERo Therapeutics Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Total Assets Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Total Assets

24.18

11.35

CERo Therapeutics Holdings Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial				-	-	9.05	7.37	6.49

CERo Therapeutics Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CERo Therapeutics Holdings's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-34.871	+	46.22
	=	11.35

CERo Therapeutics Holdings's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	-3.702	+	10.194
	=	6.49

CERo Therapeutics Holdings (NAS:CERO) Total Assets Explanation

Total Assets is connected with ROA %.

CERo Therapeutics Holdings's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-16.912	/	( (7.371	+	6.492)	/ 2 )
	=	-16.912	/	6.9315
	=	-243.99 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CERo Therapeutics Holdings's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0	/	( (7.371	+	6.492)	/ 2 )
=	0	/	6.9315
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CERo Therapeutics Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.